From: Harnessing tumor-associated macrophages as aids for cancer immunotherapy
Action | TAM-targeted agent | Checkpoint blockade | Clinical phase (status) | Tumor type | Effect | Clinical trials |
---|---|---|---|---|---|---|
Targeting TAM recruitment and survival | Emactuzumab (CSF1R inhibitor) | Atezolizumab (PD-L1 antibody) | Phase I (Recruiting) | Locally advanced or metastatic solid tumors | NA | NCT02323191 |
ARRY-382 (CSF1R antagonists) | Pembrolizumab (PD-1 antibody) | Phase I/II (Active, not recruiting) | Advanced solid tumors | NA | NCT02880371 | |
Pexidartinib (anti-CSF1R) | Durvalumab (PD-L1 antibody) | Phase I (Active, not recruiting) | Colorectal cancer; Pancreatic cancer; Metastatic cancer; Advanced cancer | NA | NCT02777710 | |
SNFX-6352 (CSF1R antagonists) | Durvalumab (PD-L1 antibody) | Phase I (Recruiting) | Solid tumor; Metastatic tumor; Locally advanced malignant neoplasm; Unresectable malignant neoplasm | Safe, Well-tolerated | NCT03238027 | |
BLZ945 (CSF1R antagonists) | PDR001 (anti-PD-1; Novartis) | Phase I/II (Recruiting) | Advanced solid tumors | NA | NCT02829723 | |
Cabiralizumab (CSF1R antagonists) | Nivolumab (anti-PD-1) | Phase I (Recruiting) | Advanced malignancies | Safe, Well-tolerated | NCT03158272 | |
AMG820 (CSF1R antagonists) | Pembrolizumab (PD-1 antibody) | Phase I/II (Active, not recruiting) | Pancreatic cancer; Colorectal cancer; Non-small cell lung cancer | NA | NCT02713529 | |
Trabectedin | Durvalumab (PD-L1 antibody) | Phase I (Recruiting) | Ovarian carcinoma; Soft tissue sarcoma | NA | NCT03085225 | |
Reprogramming TAMs to antitumor macrophages | APX005M (CD40 agonistic antibody) | Nivolumab (anti-PD-1) | Phase I/II (Recruiting) | Non-small cell lung cancer; Metastatic melanoma | NA | NCT03123783 |
Selicrelumab (CD40 agonist) | Atezolizumab (PD-L1 antibody) | Phase I (Recruiting) | Solid tumors | NA | NCT02304393 | |
IPI-549 (PI3Kγ inhibitors) | Nivolumab (anti-PD-1) | Phase I (Recruiting) | Advanced solid tumor; non-small cell lung cancer; melanoma; breast cancer | NA | NCT02637531 | |
TTI-621 (SIRPα-IgG1 Fc) | Nivolumab (anti-PD-1); Pembrolizumab (PD-1 antibody); Atezolizumab (PD-L1 antibody); Durvalumab (PD-L1 antibody) | Phase I (Recruiting) | Solid tumors; melanoma; merkel-cell carcinoma; squamous cell carcinoma; breast carcinoma | NA | NCT02890368 | |
TTI-621 (SIRPα-IgG4 Fc) | Nivolumab (anti-PD-1); Pembrolizumab (PD-1 antibody); | Phase I (Recruiting) | Lymphoma; myeloma | NA | NCT03530683 | |
GSK3145095 (RIP inhibitor) | Pembrolizumab (PD-1 antibody) | Phase I/II (Recruiting) | Neoplasms; pancreatic | NA | NCT03681951 | |
NKTR262 (TLR7/8 agonist) | Nivolumab (anti-PD-1) | Phase I/II (Recruiting) | Melanoma; merkel cell carcinoma; breast cancer; renal cell carcinoma; colorectal cancer | NA | NCT03435640 |